Sorrento Therapeutics Inc. [NASDAQ: SRNE] traded at a high on 06/17/22, posting a 6.33 gain after which it closed the day’ session at $1.68. The company report on June 14, 2022 that Scilex Holding Company, a Sorrento Company, enters into an agreement for an exclusive license with ROMEG Therapeutics, LLC, for the right to commercialize Gloperba®, an FDA-approved prophylactic treatment for painful gout flares in adults, in the US.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
Gloperba is an FDA-approved, oral medication for treating painful gout flares in adults.
Gout is a painful arthritic disorder affecting an estimated 8.7 million people in the United States1. As gout cases increase every year, treatment requirements increase. The gout treatment market is large and projected to be $8.3 billion in the US by 2025 and has a compound annual growth rate of 16% with a well-defined area of unmet need.
The results of the trading session contributed to over 20558469 shares changing hands. Over the past one week, the price volatility of Sorrento Therapeutics Inc. stands at 9.68% while the volatility over the past one month is 8.05%.
The market cap for SRNE stock reached $614.49 million, with 337.12 million shares outstanding and 312.41 million shares in the current float. Compared to the average trading volume of 9.62M shares, SRNE reached a trading volume of 20558469 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Sorrento Therapeutics Inc. [SRNE]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for SRNE shares is $21.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on SRNE stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
B. Riley Securities have made an estimate for Sorrento Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on January 29, 2021. While these analysts kept the previous recommendation, Alliance Global Partners raised their target price to Buy. The new note on the price target was released on January 21, 2021, representing the official price target for Sorrento Therapeutics Inc. stock. Previously, the target price had yet another raise from $24 to $30, while H.C. Wainwright kept a Buy rating on SRNE stock.
The Average True Range (ATR) for Sorrento Therapeutics Inc. is set at 0.14, with the Price to Sales ratio for SRNE stock in the period of the last 12 months amounting to 10.78. The Price to Book ratio for the last quarter was 2.51, with the Price to Cash per share for the same quarter was set at 0.74.
How has SRNE stock performed recently?
Sorrento Therapeutics Inc. [SRNE] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 11.26. With this latest performance, SRNE shares gained by 11.26% in over the last four-week period, additionally sinking by -71.67% over the last 6 months – not to mention a drop of -80.47% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SRNE stock in for the last two-week period is set at 53.55, with the RSI for the last a single of trading hit 57.00, and the three-weeks RSI is set at 50.28 for Sorrento Therapeutics Inc. [SRNE]. The present Moving Average for the last 50 days of trading for this stock 1.6320, while it was recorded at 1.5380 for the last single week of trading, and 4.2116 for the last 200 days.
Sorrento Therapeutics Inc. [SRNE]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Sorrento Therapeutics Inc. [SRNE] shares currently have an operating margin of -695.68 and a Gross Margin at +67.54. Sorrento Therapeutics Inc.’s Net Margin is presently recorded at -809.63.
Return on Equity for this stock declined to -351.23, with Return on Assets sitting at -62.45.
Sorrento Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.60 and a Current Ratio set at 1.60.
Earnings analysis for Sorrento Therapeutics Inc. [SRNE]
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for SRNE. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Sorrento Therapeutics Inc. go to 37.00%.
Insider trade positions for Sorrento Therapeutics Inc. [SRNE]
There are presently around $218 million, or 33.60% of SRNE stock, in the hands of institutional investors. The top three institutional holders of SRNE stocks are: STATE STREET CORP with ownership of 33,960,884, which is approximately 132.676% of the company’s market cap and around 0.50% of the total institutional ownership; BLACKROCK INC., holding 22,034,889 shares of the stock with an approximate value of $37.02 million in SRNE stocks shares; and VANGUARD GROUP INC, currently with $26.71 million in SRNE stock with ownership of nearly 1.33% of the company’s market capitalization.
Positions in Sorrento Therapeutics Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 124 institutional holders increased their position in Sorrento Therapeutics Inc. [NASDAQ:SRNE] by around 43,120,464 shares. Additionally, 77 investors decreased positions by around 5,935,461 shares, while 69 investors held positions by with 80,653,797 shares. The mentioned changes placed institutional holdings at 129,709,722 shares, according to the latest SEC report filing. SRNE stock had 38 new institutional investments in for a total of 5,383,151 shares, while 39 institutional investors sold positions of 3,609,075 shares during the same period.